SCHEMBL2118535

SCHEMBL2118535

COc1cncc(S(=O)(=O)Nc2cc(-c3ccc(C)s3)ccc2C)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.43
ALDH1A1 P00352 2/20 0.42
CYP2C9 P11712 1/20 0.42
TSHR P16473 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
USP2 O75604 1/20 0.42
USP8 P40818 1/20 0.42
PRF1 P14222 3/20 0.41
HSD17B1 P14061 1/20 0.40
HSD17B2 P37059 1/20 0.40
KEAP1 Q14145 1/20 0.40
PIK3CG P48736 1/20 0.39
FFAR4 Q5NUL3 1/20 0.39
DRD2 P14416 1/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
DRD3 P35462 1/20 0.38
HTR6 P50406 1/20 0.38
NAMPT P43490 1/20 0.38
GHSR Q92847 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2119515 0.89 CCR9 (0.40) MAPTALDH1A1CYP2C9TSHRNPSR1
SCHEMBL2118227 0.85 GHSR (0.47) MAPTALDH1A1CYP2C9TSHRNPSR1
SCHEMBL2119624 0.81 SLC40A1 (0.47) MAPTALDH1A1PRF1HSD17B1HSD17B2
SCHEMBL2117419 0.80 USP2 (0.42) MAPTALDH1A1CYP2C9TSHRNPSR1
SCHEMBL2116804 0.80 KIT (0.46) MAPTALDH1A1CYP2C9TSHRNPSR1
SCHEMBL2117810 0.80 HSD17B1 (0.47) MAPTALDH1A1CYP2C9HSD17B1HSD17B2
SCHEMBL2119972 0.80 MAPT (0.42) MAPTALDH1A1CYP2C9TSHRNPSR1
SCHEMBL2121581 0.79 TRIM24 (0.49) MAPTALDH1A1CYP2C9TSHRNPSR1
SCHEMBL2119304 0.78 ALDH1A1 (0.43) MAPTALDH1A1CYP2C9TSHRNPSR1
SCHEMBL2120887 0.78 ALDH1A1 (0.40) MAPTALDH1A1CYP2C9TSHRNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1A, HIF1AN, EGLN3 MAPT 4747/4885ALDH1A1 1063/4885CYP2C9 2049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.